Antihistamine treatment for allergic rhinitis: Different routes, different outcomes?

Allergy and Asthma Proceedings

Volumn 30, Issue 6, 2009, Pages 589-594

  Chipps, Bradley E ^a   Harder, Julia M ^a  

^a Capital Allergy and Respiratory Disease Center   (United States)

Author keywords

Allergic rhinitis; Azelastine; Intranasal antihistamines; Nasal congestion; Olopatadine; Onset of action; Oral antihistamines; Quality of life; Safety; Second generation antihistamines

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEPRO; AZELASTINE; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; FEXOFENADINE; FLUTICASONE; HISTAMINE; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MONTELUKAST; OLOPATADINE; PATANASE; PLACEBO; PSEUDOEPHEDRINE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DROWSINESS; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIPHORA; HUMAN; NOSE CONGESTION; PRURITUS; RHINOCONJUNCTIVITIS; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; COST OF ILLNESS; HISTAMINE ANTAGONISTS; HISTAMINE RELEASE; HUMANS; INFLAMMATION MEDIATORS; PRACTICE GUIDELINES AS TOPIC; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; UNITED STATES;

EID: 73649139204     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3287     Document Type: Conference Paper

References (34)

1. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 29:600-608, 2008.
2. Blaiss, M, Derebery J, Hadley J, et al. Allergies in America: A Landmark Survey of Nasal Allergy Sufferers. Executive Summary: Adult. Available online at www.myallergiesinamerica.com; last accessed April 15, 2009.
3. Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 136:S107-S124, 2007.
4. Blaiss MS. Pediatric allergic rhinitis: Physical and mental complications. Allergy Asthma Proc 29:1-6, 2008.
5. Meltzer EO, Nathan RA, Selner JC, et al. Quality of life and rhinitis symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 99:S815-S819, 1997.
6. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81:478-518, 1998.
7. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S77, 2008.
8. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63:S8-S160, 2008.
9. Meltzer EO, Hampel FC, Ratner PH, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 95:600-606, 2005.
10. Fairchild CJ, Meltzer EO, Roland PS, et al. Comprehensive report of the efficacy, safety, quality of life, and work impact of olopatadine 0.6% and olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc 28:716-723, 2007.
11. MedPointe Healthcare, Inc. Astelin package insert. Somerset, NJ; 2006. Available online at www.astelin.com; last accessed April 23, 2009.
12. Lumry W, Prenner B, Corren J, and Wheeler W. Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. Ann Allergy Asthma Immunol 99:267-272, 2007.
13. Berger WE, White MV, and Rhinitis Study Group. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 91:205-211, 2003.
14. Ratner PH, Hampel FC, Amar NJ, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol 95:474-479, 2005.
15. Berger W, Hampel F Jr, Bernstein J, et al. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 97:375-381, 2006.
16. Kaliner MA, Storms W, Tilles S, et al. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 mug in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 30:255-262, 2009.
17. Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:74-81, 2008.
18. Meda Pharmaceuticals, Inc. Astepro Clinical Study information. Available online at www.astepro.com; last accessed May 1, 2009.
19. Patel P, Roland PS, Marple BF, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg 137:918-924, 2007.
20. Alcon Laboratories, Inc. Patanase package insert. Sinking Spring, PA; 2008. Available online at www.patanase.com; last accessed April 23, 2009.
21. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: Olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 28:592-599, 2007.
22. Meltzer EO, Garadi R, Laforce C, et al. Comparative study of sensory attributes of two antihistamine nasal sprays: Olopatadine 0.6% and azelastine 0.1%. Allergy Asthma Proc 29:659-668, 2008.
23. Sacks H. Poster presented at the 46th Annual Scientific Session of the Western Society of Allergy, Asthma and Immunology, Kona, Hawaii, January 21-25, 2008.
24. Asthma and Allergy Foundation of America. Consumer Survey 2005. Available online at www.aafa.org; last accessed May 10, 2009.
25. Schad CA, and Skoner DP. Antihistamines in the pediatric population: Achieving optimal outcomes when treating seasonal allergic rhinitis and chronic urticaria. Allergy Asthma Proc 29:7-13, 2008.
26. Berger WE, Schenkel EJ, and Mansfield LE. Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 89:485-491, 2002.
27. Howarth PH, Stern MA, Roi L, et al. Double-blind, plabebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 104:927-933, 1999.
28. Bachert C, Bousquet J, Canonica GW, et al. XPERT Study Group. Levocetirizine improves quality of life and reduces cost in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 114:838-844, 2004.
29. Warner JO. Early Treatment of the Atopic Child Study Group. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol 108:929-937, 2001.
30. Greisner WA III. Onset of action for the relief of allergic rhinitis symptoms with second-generation antihistamines. Allergy Asthma Proc 25:81-83, 2004.
31. Day JH, Briscoe M, Rafeiro E, et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: Confirmation of a test system. Ann Allergy Asthma Immunol 87:474-481, 2001.
32. Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 132:354-363, 2000.
33. Spencer CM, Faulds D, and Peters DH. Cetirizine: A reappraisal of its pharmacologic properties and therapeutic use in selected allergic disorders. Drugs 46:1055-1080, 1993.
34. Mann RD, Pearce GL, Dunn N, et al. Sedation with "nonsedating" antihistamines: Four prescription-event monitoring studies in general practice. BMJ 320:1184-1186, 2000.